Head-to-head · Value Score
Alan Meds vs Sprout Health
Two GLP-1 deals, scored on the same six factors. Alan Meds lands a Value Score of 90, Sprout Health a 86. Here's who gives you the honest lower price — and where each one bites back.
Alan Meds
#5 · Grade A · Best Value
Est. first month
$99/mo
Save ~93% vs brand-nameSprout Health
#22 · Grade A- · Great Deal
Est. first month
$149/mo
Save ~89% vs brand-nameThe verdict
Alan Meds takes it on Value Score, 90 to 86 — an est. $99/mo first month, with no teaser step-up baked in. Sprout Health isn't out of it: Patients who want a low compounded entry price but the option of brand-name Wegovy or Zepbound on the same account, with minimal onboarding.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | Alan Meds | Sprout Health |
|---|---|---|
| Value Score | 90 (A) | 86 (A-) |
| Est. first month | $99/mo | $149/mo |
| Save vs brand-name | ~93% | ~89% |
| Semaglutide | $99/mo | $149/mo |
| Tirzepatide | $145/mo | $199/mo |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Flat — no step-up |
| Coverage | All 50 states | Not disclosed |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
Alan Meds
Double-digit semaglutide ($99) and a $145 tirzepatide, both nationwide, with an oral route for the needle-shy.
Why it's a deal
- $99 flat semaglutide and a low $145 tirzepatide
- Available in all 50 states
- Offers an oral/sublingual route
The fine print
- Not LegitScript-certified — do your own pharmacy diligence
- Newer operator with a thin public track record
Sprout Health
A LegitScript-certified desk that pairs low-cost compounded semaglutide and tirzepatide with a real brand-name Wegovy and Zepbound path — and a near-frictionless, often visit-free start.
Why it's a deal
- LegitScript-certified with a listed address and contact line
- Both compounded ($149 semaglutide / $199 tirzepatide) and a genuine brand-name Wegovy/Zepbound route
- Low-friction intake — no labs and often no telehealth visit required
The fine print
- Compounded semaglutide and tirzepatide are not FDA-approved
- No oral or sublingual route — injectable only
- Thin transparency — no named medical director, and state availability is quiz-gated
- "No labs, no visit" convenience also means lighter clinical oversight
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.